Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Castle Biosciences Q3 Adj. EPS $(0.02) Beats $(0.52) Estimate, Sales $83.043M Beat $71.209M Estimate

Author: Benzinga Newsdesk | November 03, 2025 04:11pm
Castle Biosciences (NASDAQ:CSTL) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.52) by 96.17 percent. This is a 125 percent decrease over earnings of $0.08 per share from the same period last year. The company reported quarterly sales of $83.043 million which beat the analyst consensus estimate of $71.209 million by 16.62 percent. This is a 3.19 percent decrease over sales of $85.782 million the same period last year.

Posted In: CSTL


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist